The FDA has approved updated labeling for Vyjuvek (beremagene geperpavec-svdt), a topical gene therapy for dystrophic epidermolysis bullosa.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback